Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series

M. Teoli, V.D. Mandel, C. Franceschini, P.L. Saraceni, M.P. Cicini, M. Ardigò

Porphyria and Rare Diseases Unit, Clinical Dermatology Department, San Gallicano Dermatological Institute – IRCCS, Rome, Italy. marco.ardigo@ifo.it

---

• Dermatology
• Oncology
• Pharmacology

BACKGROUND: Treatment choices for patients with advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS) who have failed first-line systemic therapies can be challenging, as several options are available. However, most evidence is based on observational and early phase studies due to the rarity of the disease. Mogamulizumab has recently been approved for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy; it has a good tolerability profile prompting its use in combination with other agents. This article aims at describing the role of the concomitant use of bexarotene with mogamulizumab in this setting.

CASES PRESENTATION: To add information in the field, we describe our experience with four patients with MF/SS who failed first- and second-line treatments and started the combination mogamulizumab in addition to bexarotene. The combination of bexarotene with mogamulizumab in patients with advanced MF/SS after the failure of bexarotene alone obtained a response in all the four patients observed. The response was maintained longer than expected.

CONCLUSIONS: The combination is promising and deserves further study.

Free PDF Download